# Program

## Session 1: Diagnosing cancer - challenges and progress
*Chair: Prof. Dr. Klaus P. Schäfer, BioLAGO*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30</td>
<td>Welcome and introduction&lt;br&gt;‘DiagNET’: a new international platform for advanced diagnostics&lt;br&gt;Dr. Jörg Schickedanz, BioLAGO / QIAGEN GmbH</td>
</tr>
<tr>
<td>09.40</td>
<td><strong>Keynote</strong>&lt;br&gt;The Promise and Predicaments of Personalized Medicine&lt;br&gt;Prof. Dr. Orla Sheils, Trinity Translational Medicine Institute, University of Dublin</td>
</tr>
<tr>
<td>10.05</td>
<td>Decision making by the tumorboard: How to turn complex data sets into information useful for a personalized therapy&lt;br&gt;Alan Coy, Roche Diagnostics GmbH</td>
</tr>
<tr>
<td>10.25</td>
<td>Using liquid biopsies to guide treatment decisions in advanced prostate cancer&lt;br&gt;Dr. Amin El-Heliebi, Medical University of Graz</td>
</tr>
<tr>
<td>10.45</td>
<td>The Her2 phenomenon in circulating tumor cells from breast cancer&lt;br&gt;Dr. Siegfried Hauch, QIAGEN GmbH</td>
</tr>
<tr>
<td>11.05</td>
<td>Plenary discussion</td>
</tr>
<tr>
<td>11.15</td>
<td>Coffee break &amp; poster sessions</td>
</tr>
</tbody>
</table>

## Session 2 – Part 1: Diagnostic concepts enabling efficient antibiotic therapies
*Chair: Dr. Simone Günther, EMC² Lake Constance*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.45</td>
<td><strong>Therapeutic drug monitoring of antibiotics in critically ill patients:</strong>&lt;br&gt;significance, challenges, and possible approach&lt;br&gt;Prof. Dr. Wolfgang Krüger, Clinic Konstanz&lt;br&gt;Dr. habil. med. Johannes Zander, Labor Dr. Brunner</td>
</tr>
<tr>
<td>12.05</td>
<td><strong>Keynote</strong>&lt;br&gt;Diagnostics of Tuberculosis-2018 and beyond: how to win the battle over multi-drug-resistance?&lt;br&gt;Dr. Harald Hoffmann, synlab MVZ Gauting</td>
</tr>
<tr>
<td>12.30</td>
<td>The role of POC-Testing to fight antibiotic resistance: what will be possible in 5 years from now?&lt;br&gt;Prof. Dr. med. Peter Luppa, Klinikum rechts der Isar der Technischen Universität München</td>
</tr>
<tr>
<td>12.50</td>
<td>Conference lunch &amp; poster sessions</td>
</tr>
</tbody>
</table>
Session 2 – Part 2: Managing diagnostics of multiresistant pathogens
Chair: Dr. Dieter Ulrich, CSEM SA

13.45

Keynote
Fast and reliable MRE detection right from the swab - fiction, science or science fiction?
Dr. Oliver Nolte, Center for Laboratory Medicine St. Gallen

14.10

Fighting multi-resistant hospital pathogens in the Netherlands – a role model for Europe?
Prof. Dr. med. Marc Bonten, University Medical Center Utrecht

14.30

Plenary discussion Session 2 Part 1+2

14.45

Snacks, networking & poster sessions

Session 3: Lifestyle & Diagnostics
Chair: Dr. Michael Steinwand, BioLAGO / Innovendia

15.30

Poster award ceremony
Moderation: Dr. Heike Brandstädt, Konstanz Research School Chemical Biology

15.40

Keynote
Diagnostic needs in diabetes and obesity management
Prof. Dr. med. Bernd Schultes, eSwiss Medical & Surgical Center

16.05

Connecting personalized lifestyle medicine activities in the Lake Constance health region
Prof. Dr. Dieter Stoll, University Albstadt-Sigmaringen / NMI at University of Tübingen
Otto Knes, SwissAnalysis AG

16.25

Panel discussion
Lifestyle biomarkers for personalized therapy: vision or reality?
- Prof. Dr. Britta Renner, University of Constance
- Prof. Dr. med. Bernd Schultes, eSwiss Medical & Surgical Center
- Dr. Dietmar Plonné, MVZ Humangenetik Ulm
- Prof. Dr. Dieter Stoll, University Albstadt-Sigmaringen / NMI University of Tübingen
- Otto Knes, SwissAnalysis AG, Tägerwilen
Moderation: Prof. Dr. Klazine van der Horst, Bern University of Applied Sciences

17.10

Outlook: Diagnostics 2030 – What will be the role of multiplexed immunoassays?
Dr. Thomas Joos, NMI Natural and Medical Sciences Institute at University of Tübingen

17.30

Closing words & networking apéro & poster session

The conference is part of the project DiagNET – diagnostics of the future which is funded by the European Union from the European Regional Development Fund within the scope of the program “Interreg V Alpenrhein-Bodensee-Hochrhein”.

DiagNET is funded by